Singapore markets open in 2 hours 30 minutes

Straits Times Index
3,316.56
-6.06(-0.18%)
S&P 500
5,304.72
+36.88(+0.70%)
Dow
39,069.59
+4.29(+0.01%)
Nasdaq
16,920.79
+184.79(+1.10%)
Bitcoin USD
68,652.63
-409.17(-0.59%)
CMC Crypto 200
1,485.61
+17.51(+1.19%)

Clinuvel Pharmaceuticals Limited (CUV.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD

Add to watchlist

15.57

+0.16

(+1.04%)

At close: 03:59PM AEST

Loading interactive chart…

Simply Wall St.
Institutions own 21% of Clinuvel Pharmaceuticals Limited (ASX:CUV) shares but retail investors control 59% of the company
Key Insights The considerable ownership by retail investors in Clinuvel Pharmaceuticals indicates that they...
Simply Wall St.
Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswire
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years